Premium
Absence of prolonged benefit of initial leukapheresis therapy for hairy cell leukemia
Author(s) -
Golomb Harvey M.,
Kraut Eric H.,
Oviatt David L.,
Prendergast Edward J.,
Stein Richard S.,
Sweet Donald L.
Publication year - 1983
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830140106
Subject(s) - leukapheresis , medicine , hairy cell leukemia , splenectomy , chlorambucil , leukemia , surgery , chemoimmunotherapy , chemotherapy , chronic lymphocytic leukemia , spleen , cyclophosphamide , stem cell , genetics , cd34 , biology
Abstract Four patients with the leukemic phase of hairy cell leukemia were treated with leukapheresis. Two patients failed to respond, and the other two had only transient responses; hematologic improvement lasted one month in one case and four months in the second. The patient with a four‐month response underwent a second series of leukapheresis resulting in a response lasting at least 8 months. Two of the four patients subsequently had an adequate trial of prolonged chlorambucil therapy and continued to have a clinical response. We conclude that leukapheresis has little to offer to the majority of hairy cell patients for the long‐term management of post‐splenectomy patients who develop the leukemic phase. However, an occasional patient can have a transient, and even, rarely, a prolonged response.